Parasitism & COVID19 Vaccines: New Challenge.

March 20, 2022 updated by: Reham Hany Mohammed, Assiut University

Evaluation of Blood Elements Changes and Different Cytokines in Helminthic and Protozoan Infected Patients in Relation to COVID19 Vaccines.

- Parasitic infection is a serious public health problem throughout the world particularly in developing countries including Egypt. The individuals infected with helminths are responding to the parasite infections by a specific Th2 type innate and adaptive immune responses. The Coronavirus Disease 2019 pandemic has affected over 169 million people and caused the death of millions worldwide. COVID vaccines with up to 95% of efficacy and effectiveness have been developed and approved by the Food and Drug Administration (FDA), USA. Moreover, it's reported that vaccination against COVID may lead to Cytokine Storm Syndrome in some vaccinated people with release of large amounts of cytokines as (IFNγ, IL-12, TNFα).

Study Overview

Status

Not yet recruiting

Detailed Description

  • Parasitic infection is a serious public health problem throughout the world particularly in developing countries including Egypt.
  • Stool examination and CBC(complete blood count) are considered as the most easily, affordable and accessible diagnostic tool to suspect the presence of parasitic infection.
  • One of the most important laboratory findings in many helminthic and protozoan infections is the high rate of peripheral blood eosinophilia. Giardia lamblia cause increased number of lymphocytes.
  • The individuals infected with helminths are responding to the parasite infections by a specific Th2 type innate and adaptive immune responses. The Th2 pattern cytokines predominate in long-term helminth infected individuals.
  • During chronic helminths infection, there is increased production of interleukin-4 (IL-4) and interleukin-10 (IL-10) as anti-inflammatory cytokines, as well as increased activation and expansion of eosinophils, mast cells and basophils.
  • In addition, IFNγ have an important inflammatory role in many protozoan parasites as Cryptosporidium, Microsporidia, Entamoeba histolytica.
  • The Coronavirus Disease 2019 pandemic has affected over 169 million people and caused the death of millions worldwide. COVID vaccines with up to 95% of efficacy and effectiveness have been developed and approved by the Food and Drug Administration (FDA), USA.
  • Moreover, it's reported that vaccination against COVID may lead to Cytokine Storm Syndrome in some vaccinated people with release of large amounts of cytokines as (IFNγ, IL-12, TNFα).

Study Type

Observational

Enrollment (Anticipated)

128

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

15 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Vaccinated and non-vaccinated individuals with COVID-19 vaccines who are known to have different parasitic infections (helminths and protozoan) and admitted to Assiut city hospitals.

Description

Inclusion Criteria:

  • Vaccinated and non-vaccinated individuals with COVID-19 vaccines who are known to have different parasitic infections (helminths and protozoan) and admitted to Assiut city hospitals.

Exclusion Criteria:

  • Bleeding disorders that may alter CBC results.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
parasitic infected individuals received COVID-19 vaccine
parasitic infected individuals with helminthic or protozoan who received COVID-19 vaccines of any type

Stool examination macroscopically for consistency, color, and presence of blood and/or mucus and microscopically using the following methods:

  • Saline and iodine wet mount.
  • Formalin-ethyl acetate sedimentation method.
  • Modified Ziehl-Nielsen staining : It was done to all cases with manifestations suggestive of protozoa.

    • Collection of peripheral blood samples for Automated CBC and blood indices evaluation.
    • Molecular detection of inflammatory cytokines level (IFNγ, TNFα) and antiinflammatory cytokines (IL4, IL10) by Real-time PCR(polymerase chain reaction).
parasitic infected individuals not received COVID-19 vaccine
parasitic infected individuals with helminthic or protozoan who don't receive COVID-19 vaccines of any type

Stool examination macroscopically for consistency, color, and presence of blood and/or mucus and microscopically using the following methods:

  • Saline and iodine wet mount.
  • Formalin-ethyl acetate sedimentation method.
  • Modified Ziehl-Nielsen staining : It was done to all cases with manifestations suggestive of protozoa.

    • Collection of peripheral blood samples for Automated CBC and blood indices evaluation.
    • Molecular detection of inflammatory cytokines level (IFNγ, TNFα) and antiinflammatory cytokines (IL4, IL10) by Real-time PCR(polymerase chain reaction).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
-Evaluation of CBC changes associated with some helminths and protozoan infected patients.
Time Frame: 3 years
3 years
- Estimation of cytokines level in some helminths and protozoan infected patients.
Time Frame: 3 years
3 years
- Correlation of CBC changes and cytokines level with COVID-19 vaccine administration.
Time Frame: 3 years
3 years

Secondary Outcome Measures

Outcome Measure
Time Frame
- study parasitic prevalence in community after COVID changes.
Time Frame: 3 years
3 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

April 1, 2022

Primary Completion (Anticipated)

October 30, 2024

Study Completion (Anticipated)

October 30, 2025

Study Registration Dates

First Submitted

January 9, 2022

First Submitted That Met QC Criteria

January 9, 2022

First Posted (Actual)

January 11, 2022

Study Record Updates

Last Update Posted (Actual)

April 1, 2022

Last Update Submitted That Met QC Criteria

March 20, 2022

Last Verified

March 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • parasitism & COVID19 vaccines

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Protozoan Infections

Clinical Trials on stool examination, blood sample collected

Subscribe